End-stage renal disease with atrial fibrillation: Uncharted territory in the modern world of anticoagulants

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 12, 2014, Pages 1639-1642

  Browne, Sandra D ^a   Mcmaster, Justin ^a   Rizvi, Syed A ^b   Ahmed, Sultan ^c  

^a SABA UNIVERSITY SCHOOL OF MEDICINE   (Netherlands)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c JAS Medical Management LLC   (United States)

Author keywords

Anticoagulant; Atrial fibrillation; Dialysis; End stage kidney disease

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; CREATININE; DABIGATRAN; RIVAROXABAN; WARFARIN;

BLOOD CLOTTING; CREATININE CLEARANCE; DRUG USE; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW;

ANTICOAGULANT; ATRIAL FIBRILLATION; DIALYSIS; END-STAGE KIDNEY DISEASE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84904688912     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.936379     Document Type: Review

References (17)

1. Winkelmayer WC, Turakhia MP. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease : Sins of omission or commission?. JAMA2014311:913-15
2. Szczech L. Atrial fibrillation: The beat is faster than the answers. Kidney Int 2012;81:432-3
3. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009;76:324-30
4. Juma S, Thomson BK, Lok CE, et al. Warfarin use in hemodialysis patients with atrial fibrillation: Decisions based on uncertainty. BMC Nephrol 2013;14:174
5. Brimble KS, Ingram AJ, Eikelboom JW, et al. Anticoagulants in patients with. atrial fibrillation and end-stage renal disease. Postgrad Med 2012;124:17-25
6. Shah M, Avgil TM, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-203
7. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc 2013;88:495-511
8. Hart RG, Eikelboom JW, Brimble KS, et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29:S71-8
9. Hart RG, Eikelboom JW, Ingram AJ, et al. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012;8:569-78
10. Perez A, Eraso L, Merli G. Implications of new anticoagulants in primary practice. In J Clin Pract 2013;67:139-56
11. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009;104:1292-5
12. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 2012;52:1388-98
13. Alexopoulos D, Xanthopoulou I, Plakomyti TE, et al. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis 2012;60:332-3
14. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9
15. Lobodzinski SS. New device for stroke prevention in atrial fibrillation as an alternative to anticoagulation drugs. Cardiol J 2009;16:375-8
16. University of Magdeburg. Left atrial appendage occlusion vs. usual care in patients with atrial fibrillation and severe chronic kidney disease (WATCHAFIB). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: Http://clinicaltrials.gov/show/ NCT02039167NLMIdentifier NCT0203916 [Last accessed 17 March 2014]
17. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of Warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-8